Core Insights - Eledon Pharmaceuticals reported significant advancements in its lead product, tegoprubart, an anti-CD40L antibody, which is being developed for immunosuppressive therapy in transplantation settings [2][5] - The company presented 24-month follow-up data from a Phase 1b long-term extension study, reinforcing the favorable safety and tolerability profile of tegoprubart [1][5] - Tegoprubart has received Orphan Drug designation from the FDA for preventing allograft rejection in liver transplantation, adding to its previous designations for pancreatic islet cell transplantation and ALS [5] Company Developments - Eledon treated over 100 patients across its transplantation programs, providing evidence that tegoprubart can address safety and efficacy issues with current transplant immunosuppression standards [2] - The company anticipates multiple milestones in 2026, including regulatory engagement for Phase 3 development in kidney transplantation and initiation of additional trials in islet and liver transplantation [2][5] Financial Performance - For the year ended December 31, 2025, Eledon's R&D expenses were $66.3 million, up from $52.0 million in 2024, driven by clinical development advancements and increased personnel [6] - General and administrative expenses decreased to $17.0 million in 2025 from $18.6 million in 2024, primarily due to lower stock-based compensation [7] - The net loss for 2025 was $45.6 million, or $0.52 per share, compared to a net loss of $36.2 million, or $0.66 per share, in 2024 [8][16]

Core Insights - Eledon Pharmaceuticals announced promising results from a pilot study on tegoprubart, an anti-CD40L monoclonal antibody, presented at the ATTD conference [1][4] - The study involved 12 adults with long-standing type 1 diabetes undergoing islet transplantation, showing significant improvements in glycemic control and islet graft function [2][3] Study Results - The pilot study enrolled 12 adults with a median diabetes duration of approximately 33 years and a mean HbA1C of about 8.0% prior to transplantation [2] - All 10 patients who were more than four weeks post-transplant achieved insulin independence and had a mean HbA1C of approximately 5.35% [3][6] - No rejection episodes or de novo donor-specific HLA antibodies were observed, indicating a favorable safety profile for tegoprubart [3][6] Company Perspective - The CEO of Eledon expressed optimism about the potential of tegoprubart to provide effective islet graft protection while minimizing the toxicities associated with traditional immunosuppressive regimens [4] - Eledon is committed to working with the FDA to seek regulatory guidance for tegoprubart's market path in islet cell transplantation [4] Funding and Future Studies - The clinical trial is funded by Breakthrough T1D, which is also supporting a second study to evaluate tegoprubart in patients with type 1 diabetes and chronic kidney disease [4]

Eledon Pharmaceuticals Conference Call Summary Company Overview - **Company**: Eledon Pharmaceuticals (NasdaqCM:ELDN) - **Focus**: Development of immunomodulatory therapies for organ transplantation, particularly kidney and islet cell transplants Key Points Industry and Product Development - **Phase 2 BESTOW Study**: Significant data generation year in 2025, focusing on CD40 ligand tegoprubart for kidney transplants [3][4] - **Progress**: Over 100 human transplant patients treated with tegoprubart, showing improved safety compared to tacrolimus, the historical standard of care [4][5] - **Islet Cell Transplantation**: All six patients in the initial study were able to stop insulin, indicating a functional cure for high-risk Type 1 diabetes [6] Clinical Data and Safety Profile - **Safety Improvements**: Tegoprubart demonstrated a significantly better safety profile than tacrolimus, with lower incidences of tremors, new-onset diabetes, and other complications [5][13][22] - **Efficacy Data**: Non-inferiority achieved in the BESTOW study regarding patient survival, organ survival, and rejection rates, although statistical superiority on kidney function was not demonstrated [11][12] - **Rejection Rates**: Slightly higher rejection rates in the tegoprubart arm, but treated patients showed better kidney function post-rejection [26][28] Regulatory and Future Plans - **FDA Engagement**: Plans to discuss Phase 3 trial design with the FDA, aiming for a trial size of at least 300 patients with a one-year endpoint [31][42] - **Orphan Drug Designation**: Recently received for liver transplantation, with plans to initiate a liver IST by the end of the year [8][50] Market Opportunity - **Target Market**: Approximately 27,000 kidney transplants occur annually in the U.S., with a strategy to capture market share from tacrolimus [43][44] - **Pricing Strategy**: Potential for competitive pricing given the high costs associated with transplant procedures and dialysis [46] Competitive Landscape - **Comparison with Belatacept (Bristol Myers Squibb)**: Eledon is positioning tegoprubart against tacrolimus rather than belatacept, which has not achieved standard of care status due to various issues [48][49] - **Market Share Goals**: Aim to replicate tacrolimus's success against cyclosporine, targeting a significant market share [44] Financial Position - **Cash Reserves**: Ended the previous year with over $130 million, providing a runway into the second quarter of the following year [58][60] Strategic Partnerships - **Collaboration Opportunities**: Open to partnerships in both islet cell and xenotransplantation technologies, aiming to leverage various advancements in the field [53][56] Additional Insights - **Patient Advocacy**: Patients have been actively sharing their positive experiences on social media, which may enhance visibility and support for the company's therapies [8] - **Long-term Data**: Upcoming updates on long-term data from Phase 1b and Phase 2 studies expected in mid to late 2026 [7][12]

Core Insights - Eledon Pharmaceuticals has received Orphan Drug designation from the FDA for tegoprubart, aimed at preventing allograft rejection in liver transplantation [1][2] - Tegoprubart has previously been designated for pancreatic islet cell transplantation and for treating amyotrophic lateral sclerosis (ALS) [1] - The company is optimistic about the potential of tegoprubart in liver transplantation, supported by preclinical evidence and plans for an investigator-sponsored trial later this year [2] Company Overview - Eledon Pharmaceuticals is a clinical-stage biotechnology company focused on developing immune-modulating therapies for life-threatening conditions [3] - The lead product, tegoprubart, is an anti-CD40L antibody with high affinity for the CD40 Ligand, which is a significant target for immunomodulatory therapies [3] - The company is conducting studies in various transplantation settings, including kidney, xenotransplantation, islet cell, liver transplantation, and ALS [3]

Company Overview - Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company focused on developing immune-modulating therapies for life-threatening conditions [3] - The lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, which has broad therapeutic potential [3] - Eledon is conducting preclinical and clinical studies in areas such as kidney allograft transplantation, xenotransplantation, islet cell transplantation, and amyotrophic lateral sclerosis (ALS) [3] Upcoming Events - David-Alexandre C. Gros, M.D., CEO, and Steven Perrin, Ph.D., President and CSO, will participate in a fireside chat at the Leerink Partners 2026 Global Healthcare Conference on March 11, 2026, at 1:40 p.m. ET [1] - A webcast replay of the session will be available on the company's website under Events [2]

Summary of Eledon Pharmaceuticals Conference Call Company Overview - **Company**: Eledon Pharmaceuticals (NasdaqCM:ELDN) - **Focus**: Development of immunosuppressive therapies for organ transplantation, particularly kidney and islet cell transplants Key Points from the Conference Call Phase 2 BESTOW Study Results - The Phase 2 BESTOW study showed promising outcomes, achieving a non-inferiority margin for a composite endpoint, which is crucial for Phase 3 approval [1] - Although the primary endpoint of kidney function was not met, the data indicated that the treatment outperformed standard care in various aspects [1][2] - Safety profile was significantly better, with a ninefold reduction in tremors and a sevenfold reduction in infection rates compared to standard care [3] Market Perception and Data Interpretation - The market may have underestimated the implications of missing the kidney function endpoint, as the approvable endpoint for kidney transplant studies is a composite endpoint unrelated to kidney function [4] - Acute rejection rates were higher in the tegoprubart arm (20%) compared to the tacrolimus arm (14%), but all rejections in the tegoprubart group occurred within the first six months [5] Phase 3 Study Planning - Eledon plans to request an end-of-phase 2 meeting with the FDA in late Q1 or early Q2 2026 to discuss the Phase 3 study design [10] - The primary endpoint for the Phase 3 study will focus on patient and graft survival, with a non-inferiority design [15][17] Long-term Data and Quality of Life Measures - Long-term follow-up data from a Phase 1b study showed no acute rejections and 100% survival, indicating potential for better long-term outcomes compared to standard care [7][8] - The Phase 3 study will include patient-reported outcomes to assess quality of life and toxicities associated with standard care [21] Commercial Opportunity - Eledon believes tegoprubart could become the new standard of care in transplantation, with potential applications in both allotransplant and xenotransplant settings [28] - The company aims to address the limitations of current therapies and believes that the infrastructure for drug administration has improved since previous launches [27] Islet Cell Program - The islet cell transplant program has shown promising results, with several patients achieving independence from insulin [31][32] - Eledon plans to transition this program into a sponsored study, with an IND filing expected by the end of 2026 [33][35] Xenotransplantation Developments - Eledon is collaborating on xenotransplantation studies, showing significant progress with genetically modified pig organs [41][42] - The company plans to supply tegoprubart as part of the immunosuppressive regimen for xenotransplantation, leveraging safety and efficacy data from ongoing studies [43] Financial Position and Future Milestones - Eledon has sufficient cash to fund operations through Q2 2027, with key milestones including the opening of INDs for kidney and islet cell transplant studies [50][51] - The company is committed to supporting ongoing research in xenotransplantation and other transplant-related studies [52] Additional Insights - The discussion highlighted the importance of managing immunosuppression protocols in clinical trials to ensure balanced treatment across study arms [23][24] - The potential for xenotransplantation to alleviate organ shortages presents a significant commercial opportunity, as many patients remain on waiting lists without receiving transplants [44]

Core Viewpoint - Eledon Pharmaceuticals is actively participating in the biotech sector, showcasing its leadership through a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026, highlighting its commitment to advancing immune-modulating therapies [1]. Company Overview - Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company focused on developing immune-modulating therapies for life-threatening conditions [3]. - The company's lead investigational product is tegoprubart, an anti-CD40L antibody that targets the CD40 Ligand, which has significant therapeutic potential [3]. - Eledon is conducting preclinical and clinical studies in various areas, including kidney allograft transplantation, xenotransplantation, islet cell transplantation, and amyotrophic lateral sclerosis (ALS) [3]. - The company is headquartered in Irvine, California, and more information can be found on its website [3].

Core Insights - Eledon Pharmaceuticals announced positive 24-month follow-up data from a Phase 1b trial of tegoprubart in kidney transplantation, showing an increase in mean estimated glomerular filtration rate (eGFR) from 67.0 mL/min/1.73 m² at 12 months to 74.2 mL/min/1.73 m² at 24 months [1][2] Company Overview - Eledon Pharmaceuticals is a clinical stage biotechnology company focused on developing immune-modulating therapies for life-threatening conditions, with its lead product being tegoprubart, an anti-CD40L antibody [3] - The company aims to leverage its expertise in anti-CD40 Ligand biology to conduct studies in various transplantation fields, including kidney allograft transplantation and amyotrophic lateral sclerosis (ALS) [3]

Core Insights - Eledon Pharmaceuticals has made significant progress in 2025, particularly with the tegoprubart clinical programs in kidney allotransplantation, islet transplantation, and xenotransplantation, showing promising results in safety and efficacy [2][3] Group 1: Clinical Trial Results - The Phase 2 BESTOW trial demonstrated tegoprubart's favorable safety and tolerability profile, reducing toxicities associated with tacrolimus, with a kidney function eGFR of 69 mL/min/1.73 m² at 12 months, the highest reported in larger trials [3] - The efficacy failure composite endpoint for tegoprubart was 22.2% compared to 17.2% for tacrolimus, indicating non-inferiority [3] - Preliminary results from six type 1 diabetes patients treated with tegoprubart post-islet transplantation showed all achieved insulin independence, with three remaining insulin-free for over a year [3] Group 2: Regulatory and Development Plans - The company plans to engage with regulatory authorities, including the FDA, to advance tegoprubart into Phase 3 development, aiming to provide a safer alternative to tacrolimus-based immunosuppression [2][4] - Anticipated milestones for 2026 include presenting 24-month data from a Phase 1 extension study at the American Society of Transplant Surgeons Winter Symposium [4][7] Group 3: Financial Developments - Eledon completed a $57.5 million financing, expected to support operations into the second quarter of 2027 [3][4]

Eledon Pharmaceuticals FY Conference Summary Company Overview - **Company**: Eledon Pharmaceuticals (NasdaqCM:ELDN) - **Focus**: Development of tegoprubart (Tego) for kidney transplantation and other transplant-related therapies Key Points Industry Context - **Transplantation Market**: Approximately 48,000 transplants are performed annually in the U.S., with 60% being kidney transplants [4][5] - **Kidney Transplant Statistics**: About 25,000 to 27,000 kidney transplants occur each year, while around 100,000 Americans are on the waiting list for transplants [5][6] Product Development and Clinical Trials - **Phase 2 BESTOW Data**: Recent results show that Tego's efficacy is not inferior to tacrolimus, the current standard of care, with a strong safety profile [1][2] - **Patient Involvement**: Over 150 patients have used Tego, with more than 100 post-transplant patients included in the study [2] - **Future Milestones**: Plans to approach the FDA regarding the path to market for kidney transplantation and other transplant types, including islet cell and xenotransplantation [3] Financial Position - **Cash Reserves**: Eledon finished the last quarter with over $93 million in cash and completed a $57.5 million financing round, providing sufficient funds until the second quarter of 2027 [2] Comparative Analysis with Tacrolimus - **Market Size**: Tacrolimus represents a $1.5 billion market, despite being over 30 years old [8] - **Safety Concerns**: Tacrolimus is nephrotoxic and associated with diabetes and hypertension, which are leading causes of kidney issues [9] - **Efficacy Metrics**: Mean eGFR (estimated Glomerular Filtration Rate) at 52 weeks was 69 for Tego compared to 66 for tacrolimus, indicating superior kidney function [12] Adverse Events (AEs) Comparison - **Tego vs. Tacrolimus**: Tego showed lower rates of proteinuria, bacteremia, hyperglycemia, and new-onset diabetes compared to tacrolimus [13][14][15][16] - **Psychological Impact**: Patients on tacrolimus may experience longer post-transplant dialysis, which can be psychologically challenging [17] Regulatory and Future Plans - **Phase 3 Trial**: Eledon plans to initiate a Phase 3 trial in the second half of the year, pending FDA discussions [18] - **Patient Enrollment**: Expected enrollment of 200-300 patients per arm for the Phase 3 trial, focusing on achieving non-inferiority in safety and efficacy [19] Market Opportunity - **Concentration of Transplant Centers**: There are about 250 transplant centers in the U.S., with 40 centers performing half of the transplants, indicating a concentrated market [6] Conclusion Eledon Pharmaceuticals is positioned to make significant advancements in the transplantation market with its product Tego, which has demonstrated promising efficacy and safety compared to the current standard of care, tacrolimus. The company is well-funded and has a clear path forward for regulatory approval and further clinical development.